Intercept Pharmaceuticals, Inc. [ICPT] to Ring The NASDAQ Stock Market Closing Bell

company logo



Intercept Pharmaceuticals, Inc. [ICPT], a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases, will visit the NASDAQ MarketSite in Times Square.

In honor of the occasion, Mark Pruzanski, M.D., Chief Executive Officer, will ring the Closing Bell.


NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio


Thursday, January 23, 2014 – 3:45 p.m. to 4:00 p.m. ET


Senthil Sundaram

NASDAQ MarketSite:
Christine Barna
(646) 441-5310

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.


A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx.


To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Intercept Pharmaceuticals, Inc. [ICPT]:

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including nonalcoholic steatohepatitis (NASH), primary biliary cirrhosis, primary sclerosing cholangitis portal hypertension and bile acid diarrhea. Intercept's other product candidates include INT-767, an orally-administered dual FXR/TGR5 agonist, and INT-777, an orally-administered TGR5 agonist. For more information about Intercept, please visit the Company's website at: www.interceptpharma.com.

About NASDAQ OMX Group:

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and approximately 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,300 listed companies with a market value of over $7 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.


Source:The NASDAQ OMX Group, Inc.

More From Press Releases